Physician profile
Nancy E Koehler
NPI 1164543716
$14,330.83
in general payments reported to CMS, 2019-2025
30 companies · $3,318 in 2025
The $3,318 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,991 · 2022: $2,382 · 2023: $2,162 · 2024: $4,478 · 2025: $3,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,960 · Consulting Fee: $1,900 · Education: $77.00 · Travel and Lodging: $21.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,959.59 |
| Consulting Fee | $1,900.00 |
| Education | $77.00 |
| Travel and Lodging | $21.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,734.50 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $2,337.24 | 2021-2025 | |
| Pfizer INC. | $1,256.72 | 2021-2025 | |
| Genzyme Corporation | $1,125.62 | 2021-2025 | |
| Incyte Corporation | $894.76 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $824.46 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $691.11 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $628.23 | 2021-2025 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $557.97 | 2021-2025 | Tremfya, Stelara, Remicade |
| Leo Pharma INC. | $535.34 | 2021-2025 | Adbry |
| Lilly USA, LLC | $477.84 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $438.43 | 2021-2025 | Otezla |
| Epi Health, LLC | $364.74 | 2021-2022 | |
| Allergan, INC. | $284.80 | 2021-2022 | |
| Galderma Laboratories, L.P. | $240.27 | 2021-2025 | Nemluvio, Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $228.56 | 2023-2025 | |
| Almirall LLC | $127.20 | 2022-2025 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $121.63 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $121.46 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $59.94 | 2021 | |
| Biofrontera INC. | $56.83 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $48.00 | 2024 | Sotyktu |
| Organon LLC | $35.94 | 2025 | Vtama |
| Intuitive Surgical, INC. | $26.23 | 2022 | |
| Dermira, INC. | $23.14 | 2021 | |
| Arcutis Biotherapeutics, INC. | $20.36 | 2024 | Zoryve |
| Botanix Sb INC | $19.15 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $19.08 | 2025 | Xtrac |
| Verrica Pharmaceuticals INC. | $16.57 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Koehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.